Summary of Jinxin Pharmaceutical Conference Call Company Overview - **Company**: Jinxin Pharmaceutical - **Industry**: Pharmaceutical Key Points Business Performance - Jinxin Pharmaceutical's finished drug business has shown continuous improvement in hospital, outpatient, and formulation export sectors, providing a solid performance guarantee for the company [2][3] - Profit is expected to achieve double-digit growth in 2025, with growth rates exceeding double digits in 2026 and beyond [2][3] - The pressure from accelerated depreciation is expected to decrease significantly after 2025, releasing approximately 100 million RMB in profit [2][3] - The main business profit is projected to reach 800 million RMB in 2025, leading to a potential company valuation of 12 billion RMB based on a 15x price-to-earnings ratio [2][3] Innovation Drug Commercialization - Significant progress has been made in the commercialization of innovative drugs, with the peak sales expectation for Tidasini raised from 1 billion RMB to 1.5 billion RMB [2][4] - The peak sales expectation for Kailaqin has also been increased from 500 million RMB to 1.5 billion RMB, providing substantial valuation flexibility for the company [2][4] Early Research and Development Focus - Jinxin Pharmaceutical is focusing on early-stage research in the cardiovascular and central nervous system (CNS) fields [2][5] - The company is developing LPA small molecule inhibitors, which have gained attention following Eli Lilly's successful Phase II clinical trial at the end of 2024 [2][5] - Other pharmaceutical companies, such as CSPC and Hengrui Medicine, have engaged in significant business development (BD) transactions related to LPA small molecule inhibitors, indicating the market's potential [2][5] - Pfizer is currently in concentrated BD negotiations with Jinxin regarding LPA small molecule inhibitors, which could lead to significant valuation flexibility if successful [2][5] Market Potential - The market potential for LPA small molecule inhibitors is highlighted by the substantial upfront payments and total licensing fees offered by major pharmaceutical companies [2][5] - Continuous monitoring of clinical progress and subsequent BD transactions is essential for assessing future opportunities [2][5]

Market Overview - The Hong Kong stock market showed mixed results on September 16, with the Hang Seng Index down 0.03% at 26,438.51 points, while the Hang Seng Tech Index rose 0.56% to 6,077.66 points [2] - The total market turnover for the day was HKD 294.07 billion, with southbound funds recording a net sell of HKD 3.189 billion [2] Stock Performance - Among the Hang Seng Index constituents, 35 stocks rose while 50 fell, with JD Health down 5.82%, Alibaba Health down 3.89%, and Sands China down 3.80%, leading the declines [4] - Notable stock movements included Ctrip Group rising over 4.09% and Meituan rebounding by 3.03% [3] - The healthcare sector saw a general decline, with CSPC Pharmaceutical down 2.47% and China Biologic Products down 2.41% [4] Key Company Developments - Jiangsu Hengrui Medicine experienced a dramatic drop of 53.73% after a significant rise of 115.58% the previous day, closing at HKD 192.00 per share [7] - Fosen Pharmaceutical's stock surged by 367.65%, reaching HKD 1.59 per share, following the approval of its diabetes medication by the National Medical Products Administration of China [10] Industry Trends - The Hang Seng Industry Index showed varied performance, with the non-essential consumer sector up 0.38% and the healthcare sector down 1.05% [6] - The Industrial 4.0 index led gains with a rise of 6.55%, while the unprofitable biotech index fell by 11.43% [6] Regulatory News - The Hong Kong Securities and Futures Commission announced a five-year ban on a former executive of Citigroup Global Markets for regulatory violations related to misleading trading practices [14]

Core Viewpoint - XinNuoWei announced on September 16 that it is a subsidiary of Shiyao Group listed on the A-share market, focusing on the research, development, production, and sales of biopharmaceuticals and functional foods, with a long-term strategy to continuously build an innovative biopharmaceutical industry platform [2] Group 1 - The company is primarily engaged in biopharmaceuticals and functional food sectors [2] - XinNuoWei aims to establish a sustainable innovative biopharmaceutical industry platform as part of its long-term development strategy [2] - The company's stock abbreviation will be processed according to the relevant regulations of the Shenzhen Stock Exchange [2]

据了解，"临床默示许可"是国家药品监督管理局针对药物临床试验申请（IND）设立的一种高效审批机 制。按照规则，药物临床试验申请在提交后经过60个公示日且未收到否定或质疑意见，即视为获得默示 许可，企业可依据提交的试验方案启动相应临床试验。 值得注意的是，药捷安康于今年6月23日登陆港交所，彼时IPO发行价格为13.15港元/股。以9月16日午 间休盘价格计算，上市未满三个月，药捷安康股价涨超46倍。面对近2500亿港元的市值规模，市场不少 声音质疑药捷安康及其在研管线能否支撑起如此高的市值？ 临床进展亮眼，短期亏损与资金压力待解 21世纪经济报道记者 韩利明 9月16日，港股上市药企药捷安康（02617.HK）延续近期强劲上涨态势，截至午间休盘，报收620港元/ 股，上涨49.4%，总市值达2460.8亿港元。回溯至9月10日，药捷安康股价开启持续上行通道，其中9月 15日涨幅尤为显著，最终暴涨115.58%报415 港元/股收盘，16日药捷安康尾盘跳水转跌6%，盘中一度涨 超60%。短期股价波动引发市场广泛关注。 从消息面来看，药捷安康此次股价异动或与公司核心产品的临床进展密切相关。9月10日，药捷安康公 ...

A股方面，百济神州、复星医药、科伦药业跌逾1%，重仓A股创新药的药ETF（562050）盘中失守20日 均线。 9月16日早盘，AH创新药板块高开后震荡走低。 港股方面，大权重多数飘绿，中国生物制药、百济神州、石药集团等多股跌逾1%，100%聚焦创新药研 发的港股通创新药ETF（520880）跌近1%，截至发稿成交超1.5亿元。 值得关注的是，港股通创新药ETF（520880）场内延续溢价交易，走低区间溢价率持续抬升，显示买盘 资金强势。截至昨日，520880已连续10日吸金，金额合计超6.1亿元。 消息面，政策利好密集袭来！9月12日，国家药监局发布《关于优化创新药临床试验审评审批有关事项 的公告》，明确提出对符合要求的创新药临床试验申请设立"30日审评审批通道"，进一步推动创新药研 发提速，助力我国医药产业高质量发展。 据国家卫健委日前介绍，我国在研新药数量占全球数量的比例超过20%，跃居全球新药研发第二位。 同日，国常会审议通过《生物医学新技术临床研究和临床转化应用管理条例（草案）》。会议指出，要 推动我国生物医学技术创新发展，加快技术研发和成果转化应用，促进生物医药产业提质升级，着力塑 造发展新优势。 ...

Core Viewpoint - The Hong Kong innovative drug ETF (159570) has seen significant growth, with a recent increase of nearly 2% and a rapid transaction volume exceeding 1.5 billion yuan in just three days, indicating strong market interest and liquidity in the sector [1][3]. Market Performance - As of September 15, the latest scale of the Hong Kong innovative drug ETF (159570) surpassed 22.5 billion yuan, leading in both scale and liquidity among its peers [1]. - The index components of the ETF showed mixed performance, with notable gains from companies like药捷安康 (over 50% increase) and 同源康医药 (over 14% increase), while others like 诺诚健华 and 百济神州 experienced declines [3]. Industry Trends - The continuous growth of Chinese innovative drugs in international markets is driven by collaborations with multinational corporations (MNCs), which benefit from China's efficient and cost-effective R&D pipelines [4]. - The innovative drug sector is currently in a transitional phase, with increased focus on international expansion and the realization of value through milestones and competitive advantages [4]. Clinical Developments - At the World Lung Cancer Conference (WCLC), several clinical data updates for Chinese innovative drugs were presented, particularly highlighting the promising results of ADC therapies [5]. - The release of clinical data for drugs like HLX43 and Eiza-bren indicates significant advancements in treatment efficacy for specific cancer patient populations [5]. Policy Environment - The National Healthcare Security Administration (NHSA) is set to release the 2025 medical insurance drug list, which will significantly impact companies involved in negotiations for drug inclusion [5]. - The approval of orphan drugs and imported PD-1/L-1 drugs for the insurance directory reflects a supportive policy environment for innovative drug development [5]. Financial Outlook - The anticipated easing of monetary policy by the Federal Reserve is expected to improve liquidity in the market, which could positively influence the financing environment for innovative drug companies [6]. - The A+H share innovative drug index has shown substantial growth, suggesting a favorable investment climate and potential for increased capital inflow [6]. Investment Recommendations - The Hong Kong innovative drug ETF (159570) is highlighted as a key investment vehicle, with a significant increase of over 109% in the past year, outperforming other indices [7][8]. - Investors are encouraged to focus on the underlying assets and the potential for T+0 trading, which enhances liquidity and trading flexibility [9].

Major Events - Different Group (06090) is set to launch its IPO from September 15 to September 18, with an expected listing date of September 23 [1] - Hesai Technology-W (02525) has received 168.65 times subscription for its public offering in Hong Kong, with a share price of HKD 212.80 [1] - Basilea Pharmaceutica-B (02616) will showcase CS2015 (OX40L/TSLP bispecific antibody) at ACAA 2025 [1] - CSPC Pharmaceutical Group (01093) has received clinical trial approval in China for ALMB-0166 to treat Parkinson's disease [1] - Kingdee International (00268) plans to acquire a 62.764% stake in Yunzhijia for HKD 68.25 million [1] - Lion Group Holdings (02562) intends to acquire a company leading in AI, blockchain, decentralized finance, and stablecoin innovation [1] - COSCO Shipping Holdings (01919) plans to invest CNY 370 million to establish a joint venture [1] - Shoujia Technology (00103) aims to set up a joint venture for a super new materials company [1] - CITIC Limited (00267) has its "data-driven high-end mining equipment intelligent factory" recognized as a 2025 excellent-level intelligent factory by the Ministry of Industry and Information Technology [1] - Eden Software (01147) has its self-developed "Easy AI multimodal content generation" algorithm approved for algorithm filing in Shenzhen [1] Operating Performance - Hong Kong Dragon Land (06968) reported a contract sales amount of approximately CNY 3.602 billion for the first eight months, a year-on-year decrease of 0.16% [1] - China Southern Airlines (01055) saw an 8-month passenger turnover increase of 5.97% year-on-year [1] - China Eastern Airlines (00670) reported an 8-month passenger turnover increase of 8.72% year-on-year [1] - Air China (00753) recorded a 2.3% year-on-year increase in passenger capacity input and a 3.2% increase in passenger turnover for August [1] - Hong Kong Technology Exploration (01137) reported an August total merchandise transaction value of HKD 678 million in its e-commerce business, a year-on-year decline of 4.5% [1]

Group 1 - The proposed sanctions by the Trump administration on innovative drugs have caused significant turmoil in the capital market, with the Hong Kong Hang Seng Biotechnology Index dropping by 7% at the opening, affecting leading companies like BeiGene and CSPC Pharmaceutical [1] - The National Medical Products Administration (NMPA) announced a reduction in the review and approval time for clinical trial applications to 30 working days, nearly halving the previous timeline, which has provided reassurance to the anxious market [1][8] - The U.S. aims to cut off the core profit path for Chinese innovative drugs through enhanced CFIUS reviews and increased FDA regulatory costs, while China is responding with accelerated approval processes and synchronized global research submissions [1][4] Group 2 - The Trump administration's draft executive order includes two main provisions targeting the key aspect of BD licensing for Chinese innovative drugs [2] - The first provision expands CFIUS reviews, requiring U.S. pharmaceutical companies to undergo mandatory safety reviews for acquiring rights to Chinese drugs in development, which could lead to longer transaction cycles and increased costs [3] - The second provision mandates more detailed FDA reviews of Chinese clinical data and higher regulatory fees for companies submitting trial data from China, raising the entry barriers for Chinese innovative drugs into the U.S. market [4] Group 3 - Data shows that the success rate for Chinese innovative drugs progressing from Phase I clinical trials to FDA approval is only 1.7%, highlighting the stringent nature of FDA approvals [4][6] - Currently, only two PD-1 inhibitors developed in China have received FDA approval, indicating the challenges faced by Chinese companies in the U.S. market [6] - The proposed U.S. measures may inadvertently strengthen the position of multinational corporations (MNCs) that are increasingly interested in Chinese innovative drugs due to their cost-effectiveness and high return on investment [7] Group 4 - The NMPA's recent policy to expedite clinical trial reviews is expected to significantly shorten the R&D cycle, enhancing China's attractiveness in the global R&D network and improving the bargaining power of local companies in international transactions [9][11] - The policy aims to create a more reliable domestic market as a "base" for innovative drug companies, especially when facing potential obstacles in international markets [9] - By 2025, the number of approved innovative drugs in China is projected to reach 43, with domestic drugs accounting for 93%, indicating a robust growth trajectory in the innovative drug sector [9][10] Group 5 - The Chinese government continues to support the development of innovative drugs through various policies, including the establishment of a comprehensive support system for R&D and payment mechanisms [10] - The introduction of a commercial health insurance directory for innovative drugs aims to provide new payment channels for high-value drugs, addressing the challenges of reimbursement under basic medical insurance [10] - The overall policy framework is designed to create a closed-loop system for the high-quality development of innovative drugs, enhancing clinical accessibility and stabilizing enterprise expectations [10][11]

Group 1 - The core viewpoint of the news is the significant stock price surge of药捷安康 (Yaojie Ankang), which rose over 124% in intraday trading on September 15, closing at 415 HKD per share, leading to a market capitalization of 164.71 billion HKD [2] -药捷安康 was established in 2014 and went public on June 23, 2025, with an initial share price of 13.15 HKD. The stock has seen a remarkable increase of 3055.89% within less than three months of its listing [2] - The stock price increase is attributed to the announcement of progress regarding its core product, Tinengotinib, which received clinical approval for treating specific breast cancer patients [3][4] Group 2 - Tinengotinib is a multi-target kinase (MTK) inhibitor that targets key pathways including FGFR/VEGFR, JAK, and Aurora, and is the first registered clinical-stage drug for treating recurrent or refractory cholangiocarcinoma (CCA) patients [3] - Clinical trial results for Tinengotinib show a 30% objective response rate (ORR) and a 93% disease control rate (DCR) among previously treated CCA patients in the U.S. [4] - The global CCA drug market is projected to reach 2 billion USD by 2024, with a compound annual growth rate (CAGR) of 16.2% from 2019 to 2024, and expected to grow to 4.6 billion USD by 2030 [4] Group 3 - In addition to Tinengotinib, the company has five other candidates in clinical stages and one in preclinical stage, but it has not yet commercialized any products and is currently operating at a loss [5] - The company reported losses of 343 million CNY in 2023, 275 million CNY in 2024, and 123 million CNY in the first half of 2025 [5] - Other billion-dollar market cap pharmaceutical companies in Hong Kong have established commercial products, raising questions about the sustainability of药捷安康's market cap without commercialized products [6]

Core Viewpoint - The innovation drug sector in the A-share and Hong Kong markets is experiencing significant fluctuations, with notable movements in ETFs focused on innovative drug development, indicating strong capital inflows and market interest [1][3]. Group 1: ETF Performance - The A-share innovation drug ETF (562050) fell by 0.61%, ending a two-day rise, while the Hong Kong innovation drug ETF (520880) briefly rose over 1% before closing down 0.15% [1]. - The Hong Kong innovation drug ETF (520880) has seen premium trading, with over 5.1 billion yuan invested last week, reflecting strong demand [1][3]. Group 2: Component Stock Performance - Significant divergence in performance among major component stocks of the Hong Kong innovation drug ETF, with notable gains from companies like Shijiazhuang Pharmaceutical Group and Hansoh Pharmaceutical, while companies like Innovent Biologics faced declines [3]. - New component stocks have shown remarkable performance, with Yaojie Ankang-B surging by 115.58% and MIRXES-B and Ying'en Biotechnology-B rising by 25.91% and 13.18% respectively [3]. Group 3: Index Adjustments - The Hong Kong innovation drug ETF (520880) underwent a "purification" adjustment on September 8, removing CXO companies and focusing solely on 14 innovative drug development firms, enhancing its representation of the sector [4]. - The adjusted index aims to provide a more accurate reflection of the performance of China's innovative drug companies, with a focus on those solely engaged in drug development [4]. Group 4: Policy and Market Trends - Recent favorable policies, including a 30-day review channel for innovative drug clinical trial applications, are expected to accelerate drug development and enhance the quality of China's pharmaceutical industry [4][5]. - The domestic demand for innovative drugs is rising, transitioning from a "cash-burning" phase to becoming a "cash cow," indicating a shift towards sustainable revenue generation [5]. - Analysts suggest that the innovation drug sector remains a core focus within the pharmaceutical industry, with ongoing policy support and increasing global competitiveness [5].